Clinical Nuclear Medicine · 1991 · 28 citations · 0 references
MedicineEndocrinologyNuclear MedicineEndocrine Nuclear MedicineEndocrine OncologyRadionuclide TherapyEndocrine ImagingPheochromocytoma ImagingRadioiodine TherapyIodine-123 Metaiodobenzylguanidine ScintigraphyIodine-123 RadiopharmaceuticalsIodine-131 RadiopharmaceuticalsIodine-131 Therapy ImagingMetaiodobenzylguanidine ImagingPheochromocytoma DetectionPheochromocytoma DiagnosisPheochromocytoma Pathology
Three patients with clinical suspicion of pheochromocytoma were studied with metaiodobenzylguanidine (MIBG) labeled with I-123 or I-131. In these three patients, marked uptake of the radiopharmaceutical was demonstrated in tissues that were subsequently proven not to be of neural crest origin. Furthermore, extensive biochemical evaluations and long-term followup definitively excluded pheochromocytoma in all three. Therefore, these three cases represent unexpected "false-positive" MIBG uptake.